Structure Therapeutics Inc.

What they do

The company uses structure-based drug discovery and computational chemistry to design oral small molecules against G-protein coupled receptors. Its most advanced candidate, aleniglipron (GSBR-1290), is an oral selective GLP-1 receptor agonist in five ongoing clinical studies for obesity, overweight and related conditions. It also has two oral amylin receptor agonists, ACCG-2671 in Phase 1 and ACCG-3535 selected as a second amylin candidate, plus preclinical programs targeting GIP and glucagon receptors. The company has no approved products and reports no product revenue.

Revenue drivers

• Aleniglipron (GSBR-1290) — Lead oral GLP-1R agonist for obesity and related conditions; no revenue today, with potential revenue dependent on future regulatory approval and commercialization.
• Amylin receptor agonists (ACCG-2671, ACCG-3535) — Oral amylin candidates in Phase 1 and development-candidate stage; no revenue, positioned for monotherapy and fixed-dose combination use.
• Preclinical GIP and glucagon programs — Discovery-stage small molecules intended for combination with the GLP-1 or amylin backbone; no revenue and no clinical-stage timeline disclosed in the excerpts.
• Potential collaboration and licensing agreements — The 10-K forward-looking statements reference future payments under collaboration and licensing agreements, but no specific agreement or revenue amount is disclosed in the excerpts.

Recent performance

The company has incurred increasing annual net losses, from $51.3 million in 2022 to $141.2 million in 2025. Operating cash flow was negative $222.2 million in 2025, compared with negative $116.6 million in 2024. Diluted EPS was negative $0.80 in 2025. As of June 30, 2026, total assets were $1.43 billion, total liabilities $71.0 million, shareholder equity $1.35 billion, and cash and equivalents $272.6 million. The August 6, 2026 earnings release stated cash, cash equivalents and short-term investments of $1.3 billion as of June 30, 2026, expected to fund operations and key clinical milestones through 2028.

Strategy

The company is advancing aleniglipron into Phase 3 through the ACCOMPLISH program for chronic weight management, with ACCOMPLISH-1 enrolling up to 3,600 patients and ACCOMPLISH-2 up to 1,100 patients with T2DM. It is developing a portfolio of oral small molecules designed for monotherapy and fixed-dose combinations, including ACCG-2671 and ACCG-3535, and plans a combination GLP-1 and amylin receptor agonist clinical trial later in 2026. The company is also building commercial capabilities, appointing John Berrios as Chief Commercial Officer. Management frames oral small molecules as potentially more accessible, scalable alternatives to injectable biologics and peptides.

Risks

• No approved products or revenue — The company has no approved products and has incurred significant operating losses since inception, with net losses rising to $141.2 million in 2025.
• Clinical and regulatory uncertainty — Aleniglipron and the amylin candidates remain subject to clinical trial outcomes and regulatory review, and the company states its structure-based discovery approach is unproven.
• Cash burn and financing need — Operating cash flow was negative $222.2 million in 2025, and future operations depend on raising additional capital if current cash does not fund planned milestones.
• Competitive obesity market — Approved injectable GLP-1R agonists already provide weight loss and cardiometabolic benefits, and the company faces competition from other oral obesity therapies in development.

Outlook

Management says topline 72-week aleniglipron ACCESS OLE data are on track for the third quarter of 2026, with body composition, type 2 diabetes/obesity and SWITCH clinical trial data on track for the fourth quarter of 2026. Initial Phase 1 single ascending dose data for ACCG-2671 and initiation of a multiple ascending dose trial are expected in the third quarter of 2026. The company also expects to initiate a combination GLP-1 and amylin receptor agonist clinical trial later in 2026. It states its $1.3 billion in cash, cash equivalents and short-term investments as of June 30, 2026 should fund operations and key clinical milestones through 2028.